Navigation Links
Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
Date:2/4/2013

PASADENA, Calif., Feb. 4, 2013 /PRNewswire/ -- CSNNewswire/Immunotech Laboratories, Inc. (PINKSHEETS:IMMB)

Company Director Mr. Bo. Linton of Immunotech Laboratories, Inc, a  Pasadena California based publicly traded company with patented "IPF" Technology  today stated Immunotech's technology  is now considered a major contender in the race for HIV & Cancer cures.  Recent information provided by the company for clinical testing results in both the HIV and Cancer sectors for terminal (Salvage) patients showed the use of the company's patented "IPF" vaccine treatments significantly reduced the number of infected cells while leaving the non infected cells in tact, and almost immediately started the regeneration of the body's natural immune system.

Mr. Linton further commented the company recently received an initial inquiry for a significant order of the company's patented HIV vaccine by an International associate for use as an "Experimental Drug".  If confirmed the initial order would be in excess of several Million Dollars. This would expand the company's operations from Research & Development to a Bio-Pharma manufacturing company.  In Africa, where approved experimental treatments are permitted, there are approximately 30 Million HIV/AIDS patients alone.

About Immunotech Laboratories

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and AIDS. Immunotech is committed to creating drugs for the better health of mankind.  Please visit Immunotechlab.com for information regarding the companies patented treatments, valuations and goals.

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Immunotech Contact
ir@immunotechlab.com

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com
www.facebook.com/Naborsgroup


'/>"/>
SOURCE Immunotech Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
2. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
3. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
4. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
5. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
6. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
7. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
8. IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
9. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
10. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
11. Nelson Laboratories to Present Cleaning Validation Guidelines at BIOMEDevice San Jose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... 24, 2017 Research and Markets has announced the ... Industry Forecast to 2025" report to their offering. ... The Global Empty Capsules Market is poised ... to reach approximately $2.9 billion by 2025. This industry ... on global as well as regional levels presented in the research scope. ...
(Date:2/24/2017)... HARRISBURG, Pa. , Feb. 24, 2017 ... Secretary of Drug and Alcohol Programs Jennifer Smith ... role in providing training for and using naloxone, a ... Mark McCullough , a recovery specialist and overdose ... naloxone by EMS providers. "A significant part ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... Congratulations to ... Elite division on February 12th. Ms. Esparza qualified into this prestigious status ... competition held in Las Vegas, Nevada. Frida is one of approximately 25 gymnasts ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most award-winning ... Gran Fondo of Marin. For the second year in a row, cyclists will ... , “We are thrilled to provide our safe, non-toxic sunscreen to over 2,000 ...
(Date:2/23/2017)... ... ... The 89th Academy Awards will be celebrated this weekend, which means it’s ... Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to the shoddiest ... for American Progress (CAP), for its report, Lessons From State Performance on NAEP: Why ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... a clinician-based audience, will be participating in Rare Disease Day events, hosted by ... In addition, Rare Disease Report, a website, weekly e-newsletter and quarterly publication, will ...
(Date:2/23/2017)... ... , ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be ... Hot,” which will begin airing on February 24, 2017. The show chronicles the weight ... reality television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted ...
Breaking Medicine News(10 mins):